List of Excipients in Branded Drug VESANOID

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
H2-Pharma LLC	VESANOID	tretinoin	61269-750	FERRIC OXIDE RED
H2-Pharma LLC	VESANOID	tretinoin	61269-750	FERRIC OXIDE YELLOW
H2-Pharma LLC	VESANOID	tretinoin	61269-750	GELATIN
H2-Pharma LLC	VESANOID	tretinoin	61269-750	GLYCERIN

VESANOID Excipient Strategy and Commercial Opportunities for Oral Tretinoin

Last updated: October 9, 2026

VESANOID is an oral tretinoin soft gelatin capsule approved for acute promyelocytic leukemia (APL). Its commercial profile is defined by a mature product, limited current exclusivity, a lipid-based formulation, and a narrow but clinically important indication. The main opportunities are generic softgel supply, excipient redesign, soy-free or lower-allergen formulations, improved stability, hospital supply contracts, and differentiated 505(b)(2) products. The largest technical constraint is tretinoin’s sensitivity to oxidation, light, and formulation variability.

What is VESANOID and how is it regulated?

VESANOID contains tretinoin, also known as all-trans retinoic acid or ATRA. It is administered orally for induction of remission in patients with APL, including patients with the t(15;17) translocation or PML/RAR-alpha gene expression confirmed by cytogenetic or molecular testing. The U.S. product is supplied as 10 mg soft gelatin capsules. [1]

Attribute	VESANOID profile
Active ingredient	Tretinoin, all-trans retinoic acid
Dosage form	Oral soft gelatin capsule
Strength	10 mg
U.S. indication	Acute promyelocytic leukemia
FDA approval	1995, NDA 19-650
Original sponsor	Hoffmann-La Roche
Current commercial status	Mature branded product with generic substitution potential
Primary regulatory pathway for copies	ANDA, subject to pharmaceutical equivalence and bioequivalence
Biologic status	Not applicable; biosimilar pathway does not apply

VESANOID is used in a high-acuity oncology setting. Treatment can cause differentiation syndrome, intracranial hypertension, hepatotoxicity, hyperlipidemia, leukocytosis, and other serious adverse reactions. The formulation strategy therefore must preserve dose accuracy and predictable exposure rather than optimize consumer convenience alone. [1]

What excipients are used in VESANOID capsules?

The VESANOID formulation uses a lipid-rich fill enclosed in a soft gelatin shell. The U.S. prescribing information identifies soybean oil, hydrogenated soybean oil, and beeswax in the capsule fill. The shell contains gelatin, glycerin, sorbitol, titanium dioxide, and colorants, including yellow iron oxide. [1]

Formulation component	Function
Soybean oil	Primary lipid vehicle and solvent system
Hydrogenated soybean oil	Increases fill-body consistency and improves physical stability
Beeswax	Structuring agent and viscosity modifier
Gelatin	Softgel shell-forming polymer
Glycerin	Plasticizer and moisture-control component
Sorbitol	Plasticizer and shell humectant
Titanium dioxide and iron oxide	Opacification and color control

The lipid vehicle is consistent with tretinoin’s poor aqueous solubility and high lipophilicity. A nonaqueous fill avoids the need for a conventional aqueous solution and supports encapsulation in a unit-dose softgel.

The label instructs patients to take VESANOID with a meal or shortly thereafter. This reflects the importance of food and lipid conditions in the absorption of an orally administered retinoid. [1] A formulation that changes the lipid vehicle could therefore alter exposure, food effect, dissolution behavior, and bioequivalence risk.

Why does the VESANOID excipient system matter commercially?

The product’s excipients create both a barrier and an opportunity. The barrier is technical: tretinoin can degrade under oxidative and photolytic conditions, and changes in the oil system may affect assay, impurities, capsule integrity, and pharmacokinetics. The opportunity is commercial: a manufacturer that solves these issues can offer a differentiated product without changing the active ingredient or indication.

The most important development variables are:

1. Tretinoin solubilization and uniformity in the fill.
2. Protection from oxygen and light.
3. Control of peroxide and aldehyde impurities in oils.
4. Softgel shell compatibility.
5. Capsule leakage and brittleness during long-term storage.
6. Food-effect and bioequivalence performance.
7. Control of degradation products, including retinoid-related impurities.

Hydrogenated oils can improve oxidative stability and fill consistency, but excessive structuring can impair dispersion or release. Beeswax can stabilize the fill but may complicate vegetarian or non-animal positioning. Gelatin remains effective for softgel manufacture, although it excludes vegan positioning and may create sourcing or religious-certification requirements.

What formulation patents protect VESANOID?

VESANOID’s original product protection is largely historical. The product was approved in the mid-1990s, and the original regulatory exclusivity period has expired. The orphan-drug exclusivity associated with the APL indication also expired years ago.

No durable market exclusivity should be assumed from the existence of the VESANOID brand. The commercial protection that remains is based on product recognition, clinical familiarity, manufacturing know-how, quality systems, and distribution rather than a clearly active, commercially blocking formulation patent.

The relevant IP questions for a new entrant are narrower:

IP issue	Commercial relevance
Original tretinoin composition patents	Generally expired or commercially nonblocking
VESANOID brand	Trademark protection may remain, but it does not block generic tretinoin
Capsule formulation claims	Must be reviewed for any surviving jurisdiction-specific rights
Manufacturing process claims	May affect suppliers even when the finished product is unpatented
New lipid or stability platform	Could support new patent filings
Method-of-use claims	Limited value if directed to the established APL indication and already disclosed
Packaging or delivery claims	Potentially useful for differentiated products

A prospective entrant should conduct a current patent search in the United States, Europe, Japan, and major oncology markets. The commercial presumption, however, is that VESANOID is a legacy product with no meaningful originator exclusivity barrier.

What is the Orange Book status of VESANOID?

VESANOID is an FDA-approved prescription drug listed under tretinoin for oral treatment of APL. Its approval is associated with NDA 19-650. The relevant generic pathway is an abbreviated new drug application for tretinoin capsules that demonstrates pharmaceutical equivalence and bioequivalence to the reference listed drug. [1,2]

The product is not a biologic and does not generate biosimilar exclusivity. An applicant does not need to replicate a biologic reference product or pursue a biosimilar application under section 351(k) of the Public Health Service Act.

For a generic applicant, the key Orange Book issues are:

• Identification of the correct reference listed drug.
• Confirmation of active ingredient, strength, dosage form, and route.
• Review of any listed patents or exclusivity codes.
• Paragraph IV certification if a listed patent remains relevant.
• Paragraph III certification if launch must wait until patent expiration.
• Demonstration of bioequivalence under FDA requirements.

Because the product is old and its primary exclusivities have expired, paragraph IV litigation risk is materially lower than for recently approved oncology drugs. Any current listed patent would need to be evaluated separately before filing.

When does VESANOID lose exclusivity and what does that mean for generic entry?

VESANOID lost its principal regulatory exclusivity long ago. The remaining commercial question is not when the brand loses exclusivity, but how much practical market remains for generic manufacturers.

Generic entry is feasible, but the market is specialized. APL is a relatively small indication compared with chronic cardiovascular, diabetes, or primary-care medicines. Demand is concentrated among hospitals, hematology centers, specialty pharmacies, and oncology distributors. A manufacturer may face limited volume but high supply expectations.

A generic launch could follow three scenarios:

Launch scenario	Likely commercial effect
One generic supplier	Limited price erosion; strong supply position
Two to three suppliers	Meaningful contracting pressure; improved hospital access
Multiple suppliers	Lower price but greater risk of supply fragmentation
Formulation-differentiated 505(b)(2) product	Premium opportunity if clinical or administration benefits are demonstrated

The main barrier is not patent clearance. It is the economics of manufacturing a stable softgel for a limited oncology market while maintaining uninterrupted supply.

Which excipient strategies could create new commercial products?

Soy-free lipid systems

The current formulation uses soybean-derived excipients. A soy-free formulation could target patients with soy sensitivity, hospital formularies with allergen restrictions, or procurement groups seeking reduced excipient complexity.

Candidate alternatives include:

• Medium-chain triglycerides.
• Refined corn, sunflower, or safflower oil.
• Structured triglycerides.
• Caprylic/capric triglyceride systems.
• Synthetic or semi-synthetic lipid vehicles.

The major development risk is that changing the oil changes tretinoin solubility, precipitation behavior, oxidation rate, and food effect. A soy-free version is more likely to fit a 505(b)(2) strategy if it delivers a clinically relevant benefit or solves a documented safety, tolerability, or supply problem.

Animal-free capsule shells

A gelatin-free softgel could use modified starch, carrageenan, or other non-gelatin polymers. This would support vegetarian, vegan, halal, or kosher positioning. The shell must still meet requirements for oxygen transmission, moisture transfer, mechanical strength, seal integrity, and dissolution.

Replacing gelatin is technically difficult in a small oncology product because development and scale-up costs may exceed the premium available from the market. The opportunity is stronger for a broader retinoid platform covering multiple products.

Improved oxidative protection

A manufacturer could optimize:

• Low-peroxide excipient grades.
• Nitrogen headspace.
• Oxygen-barrier blister packaging.
• Light-protective containers.
• Antioxidant systems compatible with oral oncology use.
• Reduced residual oxygen during encapsulation.
• Lower-temperature processing.

Antioxidants require careful toxicological and regulatory assessment. They may also create new impurity pathways. Packaging changes are often a lower-risk first step than adding a new chemical stabilizer.

Modified-release or reduced-frequency dosing

A modified-release product could seek improved tolerability or simplified administration. This opportunity is limited because VESANOID is used in a tightly managed induction regimen, and exposure timing may affect clinical outcomes. A modified-release product would require substantial pharmacokinetic and clinical justification and would likely be more appropriate for a 505(b)(2) application than a conventional ANDA.

Pediatric and hospital-use presentations

APL occurs in pediatric patients, and a liquid, sprinkle, or smaller-dose presentation could address administration challenges. Tretinoin’s instability and solubility create substantial hurdles for aqueous liquids. A multiparticulate or lipid-based sachet may offer a more practical path than a conventional oral solution.

How strong is the patent estate for a new VESANOID competitor?

The legacy VESANOID estate is commercially weak compared with newer oncology products. The stronger protection opportunities are available to a new entrant that develops a distinct formulation or delivery system.

Asset type	Patent potential
Conventional tretinoin capsule	Low
New soy-free lipid vehicle	Moderate
Novel oxygen-control packaging	Moderate
Gelatin-free softgel	Moderate
Pediatric multiparticulate	Moderate to strong if technically distinct
Modified-release tretinoin	Stronger, but higher clinical burden
New indication	Potentially strong, subject to clinical evidence
Manufacturing process with improved impurity control	Moderate

A new patent estate should focus on composition, fill ratios, impurity thresholds, stability performance, dissolution, and manufacturing controls. Broad claims covering tretinoin alone would face substantial prior-art challenges.

What manufacturing and supply-chain barriers affect VESANOID opportunities?

Softgel manufacturing is a specialized capability. The supplier must control fill viscosity, gelatin ribbon formation, seam integrity, drying, polishing, and packaging. Tretinoin adds sensitivity to light, oxygen, and heat.

Critical supply-chain risks include:

• Availability of pharmaceutical-grade low-peroxide oils.
• Consistent beeswax and hydrogenated oil quality.
• Softgel shell raw-material qualification.
• Retinoid contamination controls.
• Light-protective packaging capacity.
• Stability testing under ICH conditions.
• Limited number of qualified softgel manufacturers.
• Oncology wholesaler and hospital-contract requirements.

A contract manufacturer with existing softgel capacity can reduce development time. However, it may have limited availability for small-volume products or require minimum batch sizes that increase inventory exposure.

What licensing and partnership opportunities exist?

The strongest licensing opportunities are formulation-based rather than brand-based. Potential partners include:

• Softgel contract manufacturers seeking oncology products.
• Generic companies without internal lipid-formulation capacity.
• Specialty pharmaceutical firms supplying hematology centers.
• Packaging companies with oxygen-barrier systems.
• Developers of gelatin-free capsules.
• Regional distributors with hospital access.
• Companies pursuing differentiated 505(b)(2) products.

A conventional generic license would likely be valued on supply reliability, regulatory readiness, and manufacturing cost. A differentiated formulation could command stronger economics if it establishes a clinically meaningful advantage and obtains its own patent protection.

What litigation and Paragraph IV risks affect VESANOID?

VESANOID is unlikely to generate the level of Paragraph IV litigation associated with recently approved branded oncology drugs. The originator’s principal barriers are historical, and a conventional generic product should face limited litigation exposure if no active Orange Book patent blocks approval.

Litigation risk could increase if:

• A new formulation patent is listed for a differentiated product.
• A 505(b)(2) applicant relies on a patented method of use.
• A new entrant claims a novel capsule or release profile.
• A supplier asserts manufacturing-process rights.
• A generic applicant uses a formulation that overlaps a later patent.

Settlement agreements should be reviewed for launch dates, authorized-generic rights, supply obligations, and restrictions on formulation changes. There is no commercial basis to assume that a historical VESANOID settlement controls future generic entry.

How does VESANOID compare with other tretinoin products?

Product category	Route	Main market	Excipient opportunity
VESANOID	Oral capsule	APL	Generic softgel and soy-free redesign
Topical tretinoin cream	Topical	Acne and photoaging	Emulsion, microsphere, and irritation reduction
Topical tretinoin gel	Topical	Acne and dermatology	Alcohol-free and controlled-release vehicles
Other oral retinoids	Oral	Oncology or dermatology	Different safety, dosing, and formulation profiles

VESANOID should not be evaluated as a volume substitute for topical tretinoin. The products have different indications, routes, dosing requirements, safety monitoring, and regulatory markets. The more relevant comparison is with other specialty oral oncology products that have low unit volume but high supply criticality.

Key Takeaways

• VESANOID is an oral 10 mg tretinoin softgel for APL.
• Its formulation uses soybean oil, hydrogenated soybean oil, beeswax, and a gelatin-based shell.
• Original regulatory and orphan exclusivities have expired.
• Generic entry is primarily an ANDA and manufacturing challenge, not a biosimilar challenge.
• The strongest excipient opportunities are soy-free lipid vehicles, improved oxidative protection, gelatin-free shells, and pediatric presentations.
• A conventional generic has limited differentiation potential and may face a small but demanding market.
• A 505(b)(2) product could support higher value if it demonstrates improved stability, administration, tolerability, or dosing convenience.
• Manufacturing controls, low-peroxide excipients, light protection, and reliable softgel capacity are central commercial requirements.
• No meaningful originator patent barrier should be assumed for the legacy product, but current Orange Book and jurisdiction-specific patent records remain controlling for any filing decision.

FAQs About VESANOID Excipient and Commercial Strategy

Is VESANOID a biologic or does it require a biosimilar application?

No. VESANOID is a small-molecule tretinoin product. A competing product would generally use an ANDA or, for a differentiated formulation or indication, a 505(b)(2) application.

Does VESANOID contain soy?

Yes. The labeled formulation contains soybean oil and hydrogenated soybean oil. This creates a potential commercial rationale for a soy-free alternative, subject to formulation and bioequivalence development.

Can VESANOID be reformulated as a tablet?

Technically possible, but a tablet would need to address tretinoin’s poor aqueous solubility, oxidative sensitivity, dissolution, food effect, and systemic exposure. A softgel or lipid-based multiparticulate is generally more aligned with the molecule’s properties.

What is the best packaging strategy for oral tretinoin capsules?

A low-oxygen, light-protective package is the most direct strategy. High-barrier blister packaging, nitrogen control, and reduced headspace can limit degradation without introducing new chemical excipients.

Is a soy-free VESANOID generic likely to receive premium pricing?

A premium would require a documented advantage, such as allergen avoidance, improved stability, reduced supply risk, or a clinically useful administration benefit. A soy-free formulation alone may support differentiation but would not automatically justify premium pricing.

References

1. U.S. Food and Drug Administration. (2023). VESANOID (tretinoin) capsules, prescribing information. FDA/DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2019). Tretinoin: Clinical pharmacology and product labeling information. FDA.
4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.
5. National Cancer Institute. (2024). Acute promyelocytic leukemia treatment information. National Cancer Institute.